[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359
Phase 1/2Recruiting 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Trial Timeline
Apr 28, 2025 โ May 28, 2032
NCT ID
NCT06710756About [203Pb]Pb-PSV359 + [212Pb]Pb-PSV359
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359 is a phase 1/2 stage product being developed by Perspective Therapeutics for Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06710756. Target conditions include Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06710756 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma